Thursday, July 3, 2025 7/3/2025

Direct CNS Delivery System for BDNF AntagoNATs using Heterotopic Mucosal Grafting for the Treatment of Parkinson's Disease

Award Number: R01NS108968
ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 01/01/2019
PERIOD OF PERFORMANCE END DATE: 08/31/2024

Group Awards By:

View Award Description

Direct CNS Delivery System for BDNF AntagoNATs using Heterotopic Mucosal Grafting for the Treatment of Parkinson's Disease - PROJECT SUMMARY The most significant obstacle in the treatment of neurological disorders is the blood-brain barrier (BBB) which prevents 98% of all potential neuropharmaceuticals from reaching the central nervous system (CNS). Brain derived neurotrophic factor (BDNF) is one of the most intensely studied targets in Parkinson’s disease (PD) as it can reverse disease progression. BDNF AntagoNATs are synthetic oligonucleotide-like compounds capable of upregulating endogenous BDNF expression. AntagoNATs solve the problems of recombinant BDNF therapies including off-target toxicity, immunogenicity, and improper post-translational modification while increasing target specificity, improving neuronal uptake, and providing appropriate subcellular compartmentalization of the expressed protein. Compounds chemically similar to AntagoNATs have been shown to be safe and have been recently FDA approved. Despite the significant promise of BDNF AntagoNAT therapies for PD, they cannot cross the BBB. Current methods to bypass the BBB are expensive, have significant complications, and cannot be easily scaled. The trans-nasal pathway to bypass the BBB holds significant promise however current techniques rely on diffusion through the olfactory mucosa and have major drawbacks including a restricted surface area, variable drug contact, unpredictable pharmacokinetics, limited mucosal residence time, and poor drug stability. This innovative proposal brings together a unique, multi- disciplinary team of experts to overcome each of these challenges. Our group has developed an innovative intranasal heterotopic mucosal grafting technique capable of delivering a wide range of high molecular weight therapeutics directly into the CNS. This method is based on established endoscopic skull base procedures that have been safely performed globally for over a decade. We have previously shown that the BDNF AntagoNAT therapeutic strategy is non-immunogenic, reduces off target toxicity, overcomes the limitations of recombinant neurotrophic protein delivery, and is capable of successfully upregulating BDNF expression in critical end organ targets following transmucosal delivery. We have further demonstrated that the mucosal grafting technique is safe, cost effective, and highly scalable. Finally, our data indicate that our dual-compartment Liposome-in-Gel (LiG) delivery system is capable of protecting oligonucleotide cargo while improving CNS distribution by providing a sustained release depot at the mucosal surface. Our overall goal is to optimize the LiG formulation, create a quantitative pharmacokinetic model of transmucosal BDNF AntagoNAT delivery using LiG, and validate the therapeutic efficacy in two complementary rodent models of PD using histologic, behavioral, and live imaging endpoints. This innovative delivery system for BDNF AntagoNATs represents a platform technology which can eliminate the BBB as a fixed barrier to delivery and enable the use of AntagoNATs in the treatment of multiple currently undruggable CNS disorders. Our proposal is specifically designed to gather the critical pre-clinical data needed to provide a rapid pathway to first-in-human trials.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2023	MASSACHUSETTS EYE AND EAR INFIRMARY	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	12/23/2024	NON-COMPETING CONTINUATION	$0
														Subtotal = $0

Issue Date FY: 2023 ( Subtotal = $504,376 )
2023	2023	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	5	1/30/2023	NON-COMPETING CONTINUATION	$50,436
2023	2023	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	5	12/12/2022	NON-COMPETING CONTINUATION	$453,940
														Subtotal = $504,376

Issue Date FY: 2022 ( Subtotal = $504,376 )
2022	2022	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	4	3/24/2022	NON-COMPETING CONTINUATION	$50,437
2022	2022	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	4	12/4/2021	NON-COMPETING CONTINUATION	$453,939
														Subtotal = $504,376

Issue Date FY: 2021 ( Subtotal = $527,042 )
2021	2021	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	003	3	7/23/2021	NON-COMPETING CONTINUATION	$0
2021	2021	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	002	3	3/15/2021	NON-COMPETING CONTINUATION	$0
2021	2021	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	3	1/18/2021	NON-COMPETING CONTINUATION	$52,704
2021	2021	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	3	11/30/2020	NON-COMPETING CONTINUATION	$474,338
														Subtotal = $527,042

Issue Date FY: 2020 ( Subtotal = $520,638 )
2020	2020	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	2	12/9/2019	NON-COMPETING CONTINUATION	$468,575
2020	2020	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	001	2	2/12/2020	NON-COMPETING CONTINUATION	$52,063
														Subtotal = $520,638

Issue Date FY: 2019 ( Subtotal = $489,884 )
2019	2019	MASSACHUSETTS EYE AND EAR INFIRMARY & PHYSICIAN STAFF, INC.	243 CHARLES ST	BOSTON	MA	02114	SUFFOLK	USA	Extramural Research Programs in the Neurosciences and Neurological Disorders	000	1	12/26/2018	NEW	$489,884
														Subtotal = $489,884

Grand Total All Awards = $2,546,316

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Direct CNS Delivery System for BDNF AntagoNATs using Heterotopic Mucosal Grafting for the Treatment of Parkinson's Disease

Award Number: R01NS108968

ORGANIZATION: NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 01/01/2019

PERIOD OF PERFORMANCE END DATE: 08/31/2024

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer